In this study investigators develope a semi-quantitative interpretation using the liver SUVmax as reference to interpret 18F-FDG PET/CT. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold (1.6 fold of liver SUVmax) or new 18F-FDG avid lesions. Investigators compare the prognostic accuracy of the liver SUVmax-based criteria with the 5-PS criteria and ΔSUVmax interpretation with respect to predicting disease progression during chemotherapy or survival in DLBCL. Furthermore,investigators improve the prognostic ability of interim PET/CT by comparing the results to the clinical prognostic factors.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
newly diagnosed DLBCL
treated using an anthracycline-containing regimen with or without rituximab
minimal follow-up at 6 months after the completion of first-line treatment
complete medical history and clinicopathological data
